CYTO Key Statistics, Chart & Performance
The current stock price of CYTO is 0.3 USD. In the past month the price decreased by -31.8%. In the past year, price decreased by -89.47%.
CYTO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.99 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.74 | 493.62B | ||
| MRK | MERCK & CO. INC. | 12.62 | 275.98B | ||
| PFE | PFIZER INC | 7.93 | 144.30B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.51 | 113.67B | ||
| ZTS | ZOETIS INC | 20.13 | 56.25B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.83 | 23.33B | ||
| VTRS | VIATRIS INC | 5.43 | 14.57B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.36 | 11.62B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.70B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.64B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.20B |
Related stock screener links
About CYTO
Company Profile
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. The firm has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.
Company Info
ALTAMIRA THERAPEUTICS LTD
Clarendon House, 2 Church Street
Hamilton ZUG BM
CEO: Thomas Meyer
Employees: 10
Phone: 410417297194
ALTAMIRA THERAPEUTICS LTD / CYTO FAQ
What does CYTO do?
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. The firm has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.
Can you provide the latest stock price for ALTAMIRA THERAPEUTICS LTD?
The current stock price of CYTO is 0.3 USD. The price decreased by -25.94% in the last trading session.
Does CYTO stock pay dividends?
CYTO does not pay a dividend.
How is the ChartMill rating for ALTAMIRA THERAPEUTICS LTD?
CYTO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does ALTAMIRA THERAPEUTICS LTD belong to?
ALTAMIRA THERAPEUTICS LTD (CYTO) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the growth outlook for ALTAMIRA THERAPEUTICS LTD?
The Revenue of ALTAMIRA THERAPEUTICS LTD (CYTO) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
CYTO Technical Analysis
CYTO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYTO. Both the profitability and financial health of CYTO have multiple concerns.
CYTO Financial Highlights
Over the last trailing twelve months CYTO reported a non-GAAP Earnings per Share(EPS) of 0.83. The EPS increased by 101.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.09% | ||
| ROE | -0.11% | ||
| Debt/Equity | 0.05 |
CYTO Forecast & Estimates
7 analysts have analysed CYTO and the average price target is 5.41 USD. This implies a price increase of 1702% is expected in the next year compared to the current price of 0.3.
For the next year, analysts expect an EPS growth of -88.67% and a revenue growth -100% for CYTO